<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">F0202</CoID>
		<CoID Type="CompanyName">Ergomed PLC</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">ERGO</IssueID>
			<IssueID Type="CUSIP">G3R92F103</IssueID>
			<IssueID Type="ISIN">GB00BN7ZCY67</IssueID>
			<IssueID Type="RIC">ERGO.L</IssueID>
			<IssueID Type="SEDOL">BN7ZCY6</IssueID>
			<IssueID Type="DisplayRIC">ERGO.L</IssueID>
			<IssueID Type="InstrumentPI">160938572</IssueID>
			<IssueID Type="QuotePI">160990978</IssueID>
			<Exchange Code="SEA" Country="GBR">SEATS (AIM Market)</Exchange>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2015-10-07</LastModified>
		<LatestAvailableAnnual>2014-12-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2015-06-30</LatestAvailableInterim>
		<Employees LastUpdated="2014-12-31">150</Employees>
		<SharesOut Date="2015-06-30" TotalFloat="10793498.0">28750000.0</SharesOut>
		<ReportingCurrency Code="GBP">British Pounds</ReportingCurrency>
		<MostRecentExchange Date="2016-02-22">0.70681</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2015-02-02T22:52:55">Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Companys therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs. The Company operates in two segments: The services business and the co-development business. The clinical development services offered by the Company include study management, site management, study physician support, safety services, regulatory and quality management, clinical data management and biostatistics, and medical writing. It has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies. The Company also has co-development deals with other companies.</Text>
		<Text Type="Financial Summary" lastModified="2015-10-07T04:39:59">BRIEF: For the six months ended 30 June 2015, Ergomed PLC revenues increased 85% to L14.5M. Net income increased 6% to L792K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Administrative expenses increase from L1.1M to L2.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from L0.04 to L0.03.</Text>
	</TextInfo>
	<contactInfo lastUpdated="2016-01-11T23:34:02">
		<streetAddress line="1">26-24 Frederick Sanger Road</streetAddress>
		<streetAddress line="2"></streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>GUILDFORD</city>
		<state-region></state-region>
		<postalCode>GU2 7YD</postalCode>
		<country code="GBR">United Kingdom</country>
		<contactName></contactName>
		<contactTitle></contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1483</city-areacode>
				<number>503205</number>
			</phone>
			<phone type="mainfax">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1483</city-areacode>
				<number>307929</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2014-07-16T11:36:19"><webSite mainCategory="Home Page">http://ergomedgroup.com</webSite><eMail mainCategory="Company Contact/E-mail">info@ergomedgroup.com</eMail></webLinks>
	<peerInfo lastUpdated="2016-01-11T23:34:02">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620201011" mnem="">Bio Therapeutic Drugs</Industry>
			<Industry type="NAICS" order="1" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="NAICS" order="2" reported="0" code="325412" mnem="">Pharmaceutical Preparation  Manufacturing</Industry>
			<Industry type="SIC" order="1" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
			<Industry type="SIC" order="2" reported="0" code="2834" mnem="">Pharmaceutical Preparations</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers>
		<officer rank="1" since="NA">
			<firstName>Miroslav</firstName>
			<mI></mI>
			<lastName>Reljanovic</lastName>
			<age></age>
			<title startYear="NA" startMonth="" startDay="" iD1="CEO" abbr1="CEO" iD2="DRC" abbr2="Dir.">Chief Executive Officer, Owner Founder, Director</title>
		</officer>
		<officer rank="2" since="01/11/2016">
			<firstName>Stephen</firstName>
			<mI>A.</mI>
			<lastName>Stamp</lastName>
			<age>54 </age>
			<title startYear="2016" startMonth="01" startDay="11" iD1="CFO" abbr1="CFO" iD2="DRC" abbr2="Dir.">Chief Financial Officer, Director</title>
		</officer>
		<officer rank="3" since="NA">
			<firstName>Neil</firstName>
			<mI>Robert</mI>
			<lastName>Clark</lastName>
			<age>53 </age>
			<title startYear="2016" startMonth="01" startDay="11" iD1="CEX" abbr1="Corp. Exec." iD2="DRC" abbr2="Dir.">Chief Executive Officer of PrimeVigilance, Director</title>
		</officer>
		<officer rank="4" since="07/01/2015">
			<firstName>Andrew</firstName>
			<mI></mI>
			<lastName>Mackie</lastName>
			<age>50 </age>
			<title startYear="2015" startMonth="07" startDay="01" iD1="EDR" abbr1="Exec. Dir." iD2="" abbr2="">Chief Business Officer, Executive Director</title>
		</officer>
		<officer rank="5" since="NA">
			<firstName>Danko</firstName>
			<mI></mI>
			<lastName>Dominis</lastName>
			<age></age>
			<title startYear="NA" startMonth="" startDay="" iD1="OTH" abbr1="Other" iD2="" abbr2="">Ergomed Head of Business Development</title>
		</officer>
		<officer rank="6" since="NA">
			<firstName>Branka</firstName>
			<mI></mI>
			<lastName>Duvnjak</lastName>
			<age></age>
			<title startYear="NA" startMonth="" startDay="" iD1="OTH" abbr1="Other" iD2="" abbr2="">Ergomed Head of Site Management</title>
		</officer>
		<officer rank="7" since="NA">
			<firstName>Terry</firstName>
			<mI>L.</mI>
			<lastName>Murdock</lastName>
			<age>49 </age>
			<title startYear="NA" startMonth="" startDay="" iD1="OTH" abbr1="Other" iD2="" abbr2="">President of North America, Executive Director of Global Clinical Operations</title>
		</officer>
		<officer rank="8" since="NA">
			<firstName>Chris</firstName>
			<mI></mI>
			<lastName>Wilson</lastName>
			<age></age>
			<title startYear="NA" startMonth="" startDay="" iD1="OTH" abbr1="Other" iD2="" abbr2="">Head of Quality and Regulatory</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="GBP" ReportingCurrency="GBP" ExchangeRate="1.00000" LatestAvailableDate="2014-12-31">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">1.67000</Ratio>
			<Ratio FieldName="NHIG" Type="N">1.87000</Ratio>
			<Ratio FieldName="NLOW" Type="N">1.55000</Ratio>
			<Ratio FieldName="PDATE" Type="D">2016-02-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">0.00329</Ratio>
			<Ratio FieldName="EV" Type="N">43.44950</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">48.01250</Ratio>
			<Ratio FieldName="AREV" Type="N">21.15500</Ratio>
			<Ratio FieldName="AEBITD" Type="N">1.88100</Ratio>
			<Ratio FieldName="ANIAC" Type="N">0.57800</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="AEPSXCLXOR" Type="N">0.02306</Ratio>
			<Ratio FieldName="AREVPS" Type="N">0.84387</Ratio>
			<Ratio FieldName="ABVPS" Type="N">0.53353</Ratio>
			<Ratio FieldName="ACSHPS" Type="N">0.15917</Ratio>
			<Ratio FieldName="ACFSHR" Type="N">0.04372</Ratio>
			<Ratio FieldName="ADIVSHR" Type="N">0.00000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="AGROSMGN" Type="N">27.27488</Ratio>
			<Ratio FieldName="AROEPCT" Type="N">6.70300</Ratio>
			<Ratio FieldName="APR2REV" Type="N">2.26956</Ratio>
			<Ratio FieldName="APEEXCLXOR" Type="N">72.41977</Ratio>
			<Ratio FieldName="APRICE2BK" Type="N">3.13009</Ratio>
			<Ratio FieldName="Employees" Type="N">150</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2015" CurFiscalYearEndMonth="12" CurInterimEndCalYear="2015" CurInterimEndMonth="12" EarningsBasis="PRX">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">1.5</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">2.82500</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">17.76596</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">29.30000</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">13.70000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">0.09400</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">0.04500</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">5.82750</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">0.00500</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
